A Phase III, Randomized, Double-blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Previously Untreated BRAF V600E/K Mutation-Positive Participants with Unresectable or Metastatic Melanoma. STARBOARD

Brief Summary

Type:
Melanoma

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04657991

Study #:
STUDY00146822

Start Date:
Jul 19, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04657991

View Complete Trial Details & Eligibility at ClinicalTrials.gov